129 related articles for article (PubMed ID: 33615533)
1. Correcting the bias of the net benefit estimator due to right-censored observations.
Péron J; Idlhaj M; Maucort-Boulch D; Giai J; Roy P; Collette L; Buyse M; Ozenne B
Biom J; 2021 Apr; 63(4):893-906. PubMed ID: 33615533
[TBL] [Abstract][Full Text] [Related]
2. An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring.
Péron J; Buyse M; Ozenne B; Roche L; Roy P
Stat Methods Med Res; 2018 Apr; 27(4):1230-1239. PubMed ID: 27487842
[TBL] [Abstract][Full Text] [Related]
3. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
4. Generalized pairwise comparisons for censored data: An overview.
Deltuvaite-Thomas V; Verbeeck J; Burzykowski T; Buyse M; Tournigand C; Molenberghs G; Thas O
Biom J; 2023 Feb; 65(2):e2100354. PubMed ID: 36127290
[TBL] [Abstract][Full Text] [Related]
5. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
[TBL] [Abstract][Full Text] [Related]
6. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
Willems S; Schat A; van Noorden MS; Fiocco M
Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
[TBL] [Abstract][Full Text] [Related]
7. Impact of correlations between prioritized outcomes on the net benefit and its estimate by generalized pairwise comparisons.
Fuyama K; Ogawa M; Mizusawa J; Kanemitsu Y; Fujita S; Kawahara T; Sakamaki K; Oba K
Stat Med; 2023 May; 42(10):1606-1624. PubMed ID: 36849124
[TBL] [Abstract][Full Text] [Related]
8. Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study.
Giai J; Maucort-Boulch D; Ozenne B; Chiêm JC; Buyse M; Péron J
Stat Med; 2021 Feb; 40(3):553-565. PubMed ID: 33140505
[TBL] [Abstract][Full Text] [Related]
9. Restricted Net Treatment Benefit in oncology.
Piffoux M; Ozenne B; De Backer M; Buyse M; Chiem JC; Péron J
J Clin Epidemiol; 2024 Jun; 170():111340. PubMed ID: 38570079
[TBL] [Abstract][Full Text] [Related]
10. Adjusting win statistics for dependent censoring.
Dong G; Huang B; Wang D; Verbeeck J; Wang J; Hoaglin DC
Pharm Stat; 2021 May; 20(3):440-450. PubMed ID: 33247544
[TBL] [Abstract][Full Text] [Related]
11. The asymptotic distribution of the Net Benefit estimator in presence of right-censoring.
Ozenne B; Budtz-Jørgensen E; Péron J
Stat Methods Med Res; 2021 Nov; 30(11):2399-2412. PubMed ID: 34633267
[TBL] [Abstract][Full Text] [Related]
12. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
13. On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes.
De Backer M; Legrand C; Péron J; Lambert A; Buyse M
Pharm Stat; 2023 Mar; 22(2):284-299. PubMed ID: 36321470
[TBL] [Abstract][Full Text] [Related]
14. Operational characteristics of generalized pairwise comparisons for hierarchically ordered endpoints.
Deltuvaite-Thomas V; Burzykowski T
Pharm Stat; 2022 Jan; 21(1):122-132. PubMed ID: 34346169
[TBL] [Abstract][Full Text] [Related]
15. Restricted mean survival time for interval-censored data.
Zhang C; Wu Y; Yin G
Stat Med; 2020 Nov; 39(26):3879-3895. PubMed ID: 32767503
[TBL] [Abstract][Full Text] [Related]
16. Fair comparisons of cause-specific and relative survival by accounting for the systematic removal of patients from risk-sets.
Wells M; Rutherford MJ; Lambert PC
Cancer Epidemiol; 2023 Oct; 86():102408. PubMed ID: 37591148
[TBL] [Abstract][Full Text] [Related]
17. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.
Péron J; Roy P; Ozenne B; Roche L; Buyse M
JAMA Oncol; 2016 Jul; 2(7):901-5. PubMed ID: 27124210
[TBL] [Abstract][Full Text] [Related]
18. Regression models for interval censored data using parametric pseudo-observations.
Johansen MN; Lundbye-Christensen S; Larsen JM; Parner ET
BMC Med Res Methodol; 2021 Feb; 21(1):36. PubMed ID: 33588771
[TBL] [Abstract][Full Text] [Related]
19. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.
Dong G; Mao L; Huang B; Gamalo-Siebers M; Wang J; Yu G; Hoaglin DC
J Biopharm Stat; 2020 Sep; 30(5):882-899. PubMed ID: 32552451
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous marginal survival estimators when doubly censored data is present.
Julià O; Gómez G
Lifetime Data Anal; 2011 Jul; 17(3):347-72. PubMed ID: 20886370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
